Mylan Settles Connecticut's EpiPen Price Claims For $8M
Mylan Pharmaceuticals has struck another deal to resolve claims that it illegally inflated prices for EpiPens, this time settling Connecticut state enforcers' allegations of antitrust and consumer protection law violations for...To view the full article, register now.
Already a subscriber? Click here to view full article